A $356 billion annual gap between list and net revenue. And a systematically overlooked contributor that contracting strategies can't fix: the patients who abandon therapy before generating a single dollar of net revenue.
The pharmaceutical industry's gross-to-net (GTN) challenge is widely understood as a contracting and pricing problem, fought at the rebate table with PBMs and payers. But a $356 billion annual gap between list and net revenue cannot be closed by negotiation alone.
A significant and systematically overlooked contributor to GTN erosion is patient abandonment: prescriptions that are written, rebate obligations that are triggered, and drugs that are never taken. This white paper presents a demand-side GTN optimization framework and demonstrates how physician-led patient education, delivered at scale via Hoot Health's platform, directly reduces abandonment, accelerates treatment initiation, and recovers net revenue that contracting strategies alone cannot capture.
The gross-to-net problem is the gap between what a drug officially costs (the list price, or WAC) and what a manufacturer actually receives after all discounts, rebates, fees, and deductions are stripped away. It is not just accounting complexity. The gap has grown so large that it distorts drug pricing, warps incentives across the entire supply chain, and falls hardest on patients and manufacturers alike.
GTN reductions for all brand-name drugs in 2024, larger than the GDP of most countries
Average discount rate reported by Janssen across its portfolio (2018 Transparency Report)
Average discount rate reported by Merck in its 2019 U.S. Pricing Transparency Report
of pharma SKUs entirely unprofitable after discounts are applied
Pharmacy Benefit Managers leverage large patient populations to secure manufacturer discounts, but their incentive structure creates a perverse cycle of ever-higher list prices and ever-deeper rebates.
Manufacturers set a high list price (WAC) to create room for rebate negotiation with PBMs.
PBMs negotiate large rebates in exchange for preferred formulary placement, which is the right for a drug to be recommended to patients.
PBMs retain a portion of those rebates as profit, creating a direct financial incentive to maximize rebate size over patient outcomes.
Manufacturers raise list prices further to fund even larger rebates, maintaining formulary position at the cost of widening the GTN gap.
Patients whose copays are based on list price, not net price, pay more out of pocket despite manufacturers receiving less. Abandonment rates climb.
Every patient who abandons therapy after a prescription is written represents gross revenue that was never converted to net revenue, with a rebate obligation potentially triggered with zero commercial return.
Standard GTN models focus on the spread between WAC and net revenue from drugs that are dispensed. But there is a pre-dispensing loss layer that rarely appears in GTN analyses, and it is enormous.
| Therapeutic Area | List Price ($/mo) | Avg Net ($/mo) | Year-1 Abandonment | Months Lost / 100K Rxs | Net Revenue at Risk |
|---|---|---|---|---|---|
| GLP-1 Agonists | $1,000 | $450 | 57% | 3.4M months | $1.53B |
| MS Therapies | $7,000 | $2,800 | 44% | 5.3M months | $14.8B |
| Biologics (RA/Psoriasis) | $3,500 | $1,400 | 42% | 5.0M months | $7.04B |
| Rare Disease | $8,000 | $3,200 | 33% | 4.0M months | $12.8B |
| Dry Eye / Ophthalmic | $600 | $270 | 50% | 3.0M months | $810M |
| Cardiovascular | $400 | $180 | 25% | 1.5M months | $270M |
Per 100,000 new prescriptions. Sources: JAMA Cardiology (GLP-1), peer-reviewed adherence literature by therapeutic area.
The answer is rarely purely financial. Research consistently shows the primary drivers of non-initiation and early discontinuation are confusion, fear, and the absence of physician reinforcement after the clinical visit.
The average physician consultation is 7 minutes. Patients leave with fragments of information and then self-educate through unreliable channels. The physician's voice, the most trusted source for treatment decisions, disappears the moment the patient walks out the door.
After leaving the clinic, patients turn to Google, WebMD, Reddit, TikTok, Facebook groups, ChatGPT, and friends and family, sources with no accountability for adherence outcomes. Only 7% call their doctor when confused post-visit.
Patients trust their physician above all other sources, yet only 7% call their doctor when confused post-visit. The rest turn to sources with no accountability for adherence outcomes. Hoot bridges this gap by delivering the physician's own voice directly to the patient's phone.
Hoot delivers the physician's voice to patients at the precise moments they are most likely to abandon therapy, producing measurable gains in initiation, adherence, and net revenue per patient.
Converts written prescriptions to first fills, recovering 100% of at-risk gross revenue per non-initiating patient. Targets the 72-hour hesitation window after the prescription is written.
7x faster treatment initiation and earlier net revenue recognition. Reduces margin compression from fixed rebate obligations that accrue regardless of patient initiation timing.
3x adherence benchmark; each retained patient generates 4 to 9 additional months of net revenue versus baseline. This is the highest-leverage GTN impact mechanism for specialty brands.
Lower confusion-driven abandonment means fewer mid-supply returns, directly reducing product return deductions in the GTN waterfall. Particularly impactful for specialty and rare disease brands.
Outcomes data shifts payer negotiations. Adherence value documented through the Hoot platform offsets formulary rebate requirements over time, a long-term GTN lever unavailable through contracting alone.
The following waterfall traces the journey of $1 billion in gross pharmaceutical revenue to final net revenue, identifying precisely where Hoot's platform creates intervention value.
Illustrative waterfall for a $1B gross revenue brand. Hoot impacts the avoidable deductions. Commercial rebates not reduced by Hoot, but formulary differentiation strategy may reduce long-term rebate depth.
Commercial operations and finance teams require a quantifiable model for evaluating any GTN optimization investment. The scenarios below use conservative 15% patient recovery assumptions with published abandonment rates.
| Variable | Baseline (No Hoot) | With Hoot |
|---|---|---|
| Annual new prescriptions | 100,000 | 100,000 |
| Year-1 abandonment rate | 55% | 38% (−15% recovery) |
| Net revenue per patient/month | $500 | $500 |
| Avg months on therapy (Year 1) | 5.4 months | 7.7 months |
| Net revenue per retained patient | $2,700 | $3,850 |
| Total net revenue (Year 1) | $121.5M | $173.3M |
| Incremental net revenue recovered | None | +$51.8M |
Conservative model assuming 15% patient recovery rate. Hoot's 3x adherence benchmark implies larger impact at higher-abandonment brands.
Pharmaceutical companies invest billions annually in patient support programs. The question for commercial operations leaders is not whether to invest but which investments produce measurable GTN outcomes.
Pharma patient services programs often measure success by program enrollment and outbound contact rates. Hoot measures success by prescription fill rates, 30/60/90-day refill completion, and physician-reported patient confidence, the metrics that directly translate to GTN outcomes.
Not all brands face equivalent GTN risk from patient abandonment. Hoot's GTN optimization impact is greatest in therapeutic contexts with high list prices, complex initiation pathways, and chronic therapy requirements.
Questions pharma commercial operations, patient services, and market access teams ask when evaluating demand-side GTN strategies.
Gross-to-net (GTN) in pharmaceuticals is the difference between a drug's Wholesale Acquisition Cost (WAC) list price and the net revenue a manufacturer actually retains after all deductions: PBM rebates, Medicaid mandatory rebates, 340B program discounts, chargebacks, distribution fees, and product returns. In 2024, total brand-name GTN reductions reached $356 billion. The gap grew because PBMs created a perverse incentive loop: larger rebates secured better formulary access, manufacturers raised list prices to fund larger rebates, and patients whose copays are based on list price faced higher out-of-pocket costs, driving abandonment rates that further erode net revenue.
Prescription abandonment is a pre-revenue GTN leak: when a patient receives a prescription but never fills it, the manufacturer loses gross revenue before GTN calculations even begin. Worse, rebate obligations may already be triggered. Year-1 abandonment rates range from 25% (cardiovascular) to 57% (GLP-1 agonists). For a brand with 100,000 annual prescriptions at $500/month net revenue, reducing abandonment by just 15% can recover over $51 million in annual net revenue, without changing a single contractual term.
KPMG reports average GTN ratios of 55% across pharma SKUs, meaning manufacturers retain only 45 cents of every list-price dollar. Up to 35% of pharma products are entirely unprofitable after discounts. Specialty categories face the widest gaps: biologics for RA and psoriasis, MS therapies, and GLP-1 agonists routinely see discounts exceeding 40–57% of list price, driven by PBM competition for formulary position in high-revenue therapeutic classes.
Traditional patient support programs (hub services, call centers, copay cards) operate downstream of the initiation decision. Physician-led patient education delivered via Hoot Health addresses the root cause of abandonment: patient confusion, fear, and absence of trusted guidance during the 72-hour hesitation window after a prescription is written. By delivering the prescribing physician's voice at precisely these moments, Hoot produces 3x adherence benchmarks and 7x faster treatment initiation at a cost of $150K–$350K annually versus $2M–$50M for comparable hub or copay programs. Net revenue ROI of 40:1–80:1 versus 5:1–15:1 for hub and copay alternatives.
GLP-1 agonists and biologics (RA/psoriasis) have the highest combined GTN risk, both scoring five stars for Hoot's optimization fit. GLP-1 agonists see 57% year-1 abandonment with net revenue at risk of $1.53B per 100,000 prescriptions. Biologics face 42% abandonment with $7.04B at risk per 100K Rxs. Rare disease ($12.8B at risk, 33% abandonment) and MS therapies ($14.8B at risk, 44% abandonment) are also priority areas due to high net revenue per patient and complex initiation pathways.
Hoot Health delivers physician-recorded or AI-generated physician avatar video content to patients via SMS and email at the precise moments of highest abandonment risk, particularly the 72-hour window after a prescription is written. Branded patient education programs using MLR-reviewed physician video content can launch in 60–90 days at $150K–$350K per year. Medical affairs content deployment programs using existing approved video assets can launch in 30–45 days at $75K–$200K. Custom pricing is available for multi-brand and enterprise agreements.
Yes. Hoot Health offers complimentary Patient Confusion Audits for pharma commercial and patient services teams. The audit maps the current patient journey for a specific brand, identifies the highest-value abandonment intervention points, and models the potential net revenue recovery using the brand's own prescription volume, therapeutic area, and net revenue data. Contact [email protected] or visit gethoot.com to request an audit.
In-Depth Analysis
For pharmaceutical commercial operations and patient services teams, gross-to-net (GTN) management has become one of the defining financial challenges of the decade. The GTN ratio, defined as the difference between a drug’s Wholesale Acquisition Cost (WAC) and the net revenue a manufacturer actually retains after rebates, discounts, chargebacks, and mandatory program deductions, has reached historic levels of erosion. In 2024, total brand-name GTN reductions hit $356 billion, according to the Drug Channels Institute’s 2025 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers.
KPMG has observed average GTN ratios of 55% across pharma SKUs, with up to 35% of products entirely unprofitable after discounts are applied. Gross-to-net differences in price changes ranged from -12.8% to +6.3% across the nine largest manufacturers in recent analyses. Janssen reported average discount rates of 47% across its portfolio in its 2018 transparency reporting; Merck reported 43.7% in its 2019 U.S. Pricing Transparency Report.
The drivers of GTN erosion are well-documented on the supply side: PBM rebate demands, Medicaid mandatory rebate obligations, 340B program pricing, formulary access concessions, and distribution fees. Commercial operations teams spend enormous resources modeling, forecasting, and negotiating these variables. What is far less discussed, and far less acted upon, is the demand-side contribution to GTN erosion.
Demand-side GTN erosion refers to revenue that disappears not because of a rebate, but because a patient never initiated therapy or abandoned it before generating meaningful net revenue. This pre-dispensing loss layer rarely appears in standard GTN waterfall analyses, yet it represents a substantial and recoverable portion of the revenue gap for specialty and chronic therapy brands.
The standard framing of prescription abandonment treats it as a patient outcomes issue, a clinical quality problem to be managed by medical affairs or patient services. But for commercial operations leaders, the financial implications are equally significant. When a patient receives a prescription and does not fill it, the manufacturer loses gross revenue entirely. In some contracting structures, rebate obligations are triggered at the point of prescription, meaning the manufacturer may incur financial liability for a patient who never receives the drug.
Year-1 abandonment and discontinuation rates by therapeutic area illustrate the scale of the problem: GLP-1 agonists see approximately 57% year-1 abandonment; MS therapies, approximately 44%; biologics for RA and psoriasis, approximately 42%; rare disease therapies, approximately 33%; dry eye and ophthalmic specialty drugs, approximately 50%; and cardiovascular medications, approximately 25%. These are not marginal numbers. They represent the majority of patients in several high-value therapeutic classes.
Research into health information seeking behavior reveals a consistent pattern: patients who receive a new prescription, particularly for specialty therapies, enter a period of intense self-research immediately following the physician visit. During this 72-hour window, which Hoot Health calls the hesitation window, patients are most likely to encounter alarming side effect profiles, confusing dosing instructions, or negative anecdotal reports that trigger abandonment.
The primary driver of abandonment in this window is not cost. It is confusion and fear in the absence of physician guidance. Patients turn to Google, WebMD, Reddit, TikTok, YouTube, Facebook groups, and increasingly to AI assistants like ChatGPT. Only 7% call their prescribing physician directly. The physician’s voice, the most trusted source for treatment decisions, is absent at precisely the moment it is most needed.
The implication for commercial operations is direct: restoring physician-led guidance during the hesitation window is not just a clinical quality initiative. It is a GTN optimization strategy. Hoot Health’s platform delivers physician-recorded video content to patients via SMS and email at programmatically defined moments in the patient journey, with particular emphasis on the 72-hour post-prescription window.
The platform operates through five distinct GTN impact mechanisms: (1) reducing pre-fill abandonment by converting written prescriptions to first fills; (2) accelerating treatment start, delivering 7x faster initiation and earlier net revenue recognition; (3) improving 12-month adherence to 3x benchmark levels, extending the patient revenue lifecycle by 4 to 9 months per patient versus baseline; (4) reducing product returns through lower confusion-driven abandonment; and (5) building formulary differentiation through documented adherence outcomes that shift payer negotiations over time.
For a brand with $1 billion in gross revenue, a standard GTN waterfall model allocates approximately $270 million to PBM and commercial rebates, $150 million to Medicaid mandatory rebates, $80 million to 340B discounts, and $40 million to distribution and chargeback fees, leaving approximately $200 million in net revenue before addressing avoidable deductions. The avoidable layer, including product returns from abandonment ($35M), pre-fill abandonment loss ($120M), and early discontinuation loss ($105M), represents $260 million in additional deductions that are, by definition, reducible through patient engagement intervention.
With Hoot’s platform, the avoidable deduction recovery across these three categories totals approximately $89 million, a 44.5% improvement in net revenue retained, from $200 million to $289 million. This represents the highest-leverage GTN optimization opportunity available to commercial operations teams, at a fraction of the cost of contractual renegotiation programs.
Hoot Health offers two primary partnership models for pharmaceutical manufacturers. The Branded Patient Education Program delivers MLR-reviewed physician video content through Hoot’s physician network and patient SMS/email infrastructure, with a 60 to 90 day launch timeline at an annual cost of $150,000 to $350,000. The Medical Affairs Content Deployment model uses existing approved video content from a brand’s medical affairs library, deploying it through Hoot’s patient communication infrastructure with a 30 to 45 day launch timeline at $75,000 to $200,000 annually. Multi-brand and enterprise pricing is available.
For commercial operations leaders evaluating the GTN optimization landscape, the core question is not whether patient education creates value (the adherence literature is unambiguous on this point). The question is whether the investment structure is designed to produce measurable GTN outcomes: prescription fill rates, 30/60/90-day refill completion, and net revenue per patient over the first 12 months of therapy. Hoot Health measures success exclusively on these metrics.
The pharmaceutical industry has spent a decade managing the gross-to-net bubble through contracting strategy. The result is a $356 billion annual gap that continues to grow despite sophisticated rebate modeling, payer negotiation, and formulary access investment. The missing dimension is the patient. Every dollar of list price that is never converted to a dispensed, adherent prescription is a dollar of gross revenue that disappears before GTN calculations even begin.
For pharma commercial operations leaders, patient services directors, and market access teams searching for new approaches to the gross-to-net challenge, physician-led patient education represents a fundamentally different kind of intervention, one that creates net revenue by protecting it, before it is lost to abandonment, confusion, and the absence of physician guidance at the critical moment of hesitation.
We map your patient journey, identify the highest-value abandonment intervention points, and model the net revenue recovery for your brand. Complimentary for pharma commercial and patient services teams.
